title: Effect of combined administration of clopidogrel and lysine acetylsalicylate versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa expression in healthy volunteers.
abstract: Platelet activation contributes to thrombotic events in cardiovascular disease. Acetylsalicylic acid (ASA) is used in combination with clopidogrel to reduce cardiovascular events. Lysine acetylsalicylate (L-ASA), also inhibits platelet activation with fewer gastrointestinal side effects than ASA. Dual therapy with L-ASA and clopidogrel may result in an antiplatelet effect with fewer side effects. We compared the antiplatelet effect of combined ASA/clopidogrel versus L-ASA/clopidogrel in healthy subjects. Fourteen volunteers (seven men and seven women, aged 25-45 years) received antiplatelet therapy during 14-day periods in the following sequence: 75 mg ASA; 160 mg L-ASA; 75 mg clopidogrel; 160 mg L-ASA plus 75 mg clopidogrel, and 75 mg ASA plus 75 mg clopidogrel. We evaluated platelet aggregation and glycoprotein IIb/IIIa activation. Our results show that administration of L-ASA/clopidogrel is as effective as ASA/clopidogrel combination.
authors.affiliation: Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Hospital General Regional Gabriel Mancera, Instituto Mexicano del Seguro Social, Mexico City, Mexico. amajlufc@prodigy.net.mx
authors.forename: Abraham
authors.initials: A
authors.lastname: Majluf-Cruz
authors.forename: Adriana Ruiz de
authors.initials: AR
authors.lastname: Chavez-Ochoa
authors.forename: Karim
authors.initials: K
authors.lastname: Majluf-Cruz
authors.forename: Erika
authors.initials: E
authors.lastname: Coria-Ramirez
authors.forename: Ignacio
authors.initials: I
authors.lastname: Pineda Del Aguila
authors.forename: Sandra
authors.initials: S
authors.lastname: Treviño-Perez
authors.forename: Lisneth
authors.initials: L
authors.lastname: Matías-Aguilar
authors.forename: Julio César
authors.initials: JC
authors.lastname: López-Armenta
authors.forename: Norma
authors.initials: N
authors.lastname: Corona de la Peña
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000096:biosynthesis* / Q000187:drug effects* / Q000502:physiology; D012016:Reference Values; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077144:Clopidogrel; D008239:Lysine; D013988:Ticlopidine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate